Hormonal
Obesity causes a significant reduction in circulating adiponectin levels, which contributes to insulin resistance, metabolic syndrome, and increased cancer risk.
If you have excess body fat, your body naturally produces less of this protective hormone, which makes you more resistant to insulin and prone to inflammation. This is a biological feedback loop, not a character flaw. Addressing the underlying adiposity through sustainable lifestyle changes can help restore normal adiponectin levels and improve metabolic health.
Adiponectin inversely correlates with body fat mass and visceral adiposity... Obesity mediates its effect on cancer progression via dysregulation of adipocytokines including increased production of oncogenic adipokine leptin along with decreased production of adiponectin.
Why this rating
The paper is a comprehensive review citing multiple human observational studies, animal models, and clinical trials, though it does not present new primary data.
Source
Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease
Sheetal Parida et al. · International Journal of Molecular Sciences · 2019
DOI 10.3390/ijms20102519
More from this paper
- Thiazolidinediones (TZDs) increase circulating adiponectin levels, particularly the high molecular weight (HMW) form, by stimulating transcription and preventing ER retention.Good
- Low levels of adiponectin are associated with an increased risk of various cancers, including breast, liver, pancreatic, prostate, ovarian, and colorectal cancers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →